These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1093294)

  • 1. Tumor inhibitory properties of anaerobic Corynebacteria.
    Woodruff MF
    Transplant Proc; 1975 Jun; 7(2):229-32. PubMed ID: 1093294
    [No Abstract]   [Full Text] [Related]  

  • 2. Corynebacterium-induced protection against artificial pulmonary metastases of a syngeneic fibrosarcoma in mice.
    Milas L; Hunter N; Withers HR
    Cancer Res; 1974 Mar; 34(3):613-20. PubMed ID: 4590922
    [No Abstract]   [Full Text] [Related]  

  • 3. Protection by Corynebacterium parvum against tumour cells injected intravenously.
    Milas L; Mujagić H
    Rev Eur Etud Clin Biol; 1972 May; 17(5):498-500. PubMed ID: 4648182
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.
    Woodruff MF; McBride WH; Dunbar N
    Clin Exp Immunol; 1974 Jul; 17(3):509-18. PubMed ID: 4549691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the toxicity of two formulations of Corynebacterium parvum in a double-blind crossover trial in patients with bronchogenic carcinoma.
    Mitcheson HD; Priestman TJ
    Clin Oncol; 1981 Sep; 7(3):179-82. PubMed ID: 7044635
    [No Abstract]   [Full Text] [Related]  

  • 6. The growth of tumours in T-cell deprived mice and their response to treatment with Corynebacterium parvum.
    Woodruff M; Dunbar N; Ghaffar A
    Proc R Soc Lond B Biol Sci; 1973 Aug; 184(1074):97-102. PubMed ID: 4147951
    [No Abstract]   [Full Text] [Related]  

  • 7. A role for T lymphocytes in tumour inhibition and enhancement caused by systemic administration of Corynebacterium parvum.
    Peters LJ; McBride WH; Mason KA; Milas L
    J Reticuloendothel Soc; 1978 Jul; 24(1):9-18. PubMed ID: 308542
    [No Abstract]   [Full Text] [Related]  

  • 8. Non-specific immunostimulation in bronchogenic cancer.
    Israel L
    Scand J Respir Dis Suppl; 1974; 89():95-105. PubMed ID: 4370224
    [No Abstract]   [Full Text] [Related]  

  • 9. [Stimulating immunity with the use of Corynebacterium parvum after resection of carcinoma of bronchial origin. Clinical aspects].
    Dangubić V; Dujić A; Lilić D; Kolasinović N; Jeremić K
    Srp Arh Celok Lek; 1982 Sep; 110(9):1017-24. PubMed ID: 7182936
    [No Abstract]   [Full Text] [Related]  

  • 10. Responsiveness of senescent mice to the antitumor properties of Corynebacterium parvum.
    Yuhas JM; Ullrich RL
    Cancer Res; 1976 Jan; 36(1):161-6. PubMed ID: 1247995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of tumor cells and activated macrophages in vitro: modulation by Corynebacterium parvum and gold salt.
    Ghaffar A; McBride WH; Cullen RT
    J Reticuloendothel Soc; 1976 Oct; 20(4):283-9. PubMed ID: 825644
    [No Abstract]   [Full Text] [Related]  

  • 12. Doxorubicin, cisplatin, and Corynebacterium parvum in non-small cell bronchogenic carcinoma.
    Drapkin R; Bjornsson S; Naeher C; Higby D; Caracandas J; Wallens WT; Kuberka N; Suh K; Siddiqi N; Henderson ES
    Cancer Treat Rep; 1980; 64(12):1367-9. PubMed ID: 7193520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer.
    Thatcher N; Honeybourne D; Wagstaff J; Carroll KB; Barber PV; Morrison JB; Crowther D
    Br J Dis Chest; 1984 Jan; 78(1):89-97. PubMed ID: 6318791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of Corynebacterium parvum on T cell dependent tumor regression.
    McBride WH; Peters LJ; Mason KA; Barrow G
    J Reticuloendothel Soc; 1980 Feb; 27(2):151-8. PubMed ID: 6965725
    [No Abstract]   [Full Text] [Related]  

  • 15. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
    Magnarin M; Bergamo A; Carotenuto ME; Zorzet S; Sava G
    Anticancer Res; 2000; 20(5A):2939-44. PubMed ID: 11062704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antineoplastic effects of egg-white lysozyme in mice bearing solid metastasizing tumors.
    Sava G; Perissin L; Zorzet S; Callerio C
    Anticancer Res; 1986; 6(2):183-6. PubMed ID: 3707053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on antitumor effect of corynebacterium parvum and pustulan on Lewis lung carcinoma in mice.
    Budzyński W
    Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):379-84. PubMed ID: 7184489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Corynebacteria--stimulators of antitumor resistance].
    Zatula DG; Zaval'niuk AK; Tofan AV
    Eksp Onkol; 1984; 6(6):12-8. PubMed ID: 6396064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
    Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
    Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunopotentiation in the treatment of malignant diseases. Cellular immunity in patients with malignoma of the lung treated with Corynebacterium parvum].
    Dujić A; Dangubić V; Lilić D; Kolasinović N
    Vojnosanit Pregl; 1982; 39(4):298-301. PubMed ID: 7147792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.